[German Translation] Prof. Curigliano and Prof. Cortes discussion focused on the use, efficacy, side effects, and management strategies of CDK4/6 inhibitors in early and metastatic breast cancer, including practical guidance on dosing, toxicity management, patient adherence, and considerations for therapy selection.
0:51Â - Overview of CDK4/6 inhibitors in breast cancer treatment.
1:13Â - Differences in efficacy and survival outcomes among palbociclib, ribociclib, and abemaciclib.
1:38Â - Risk factors and recurrence in ER-positive, HER2-negative early breast cancer.
3:39Â - Key clinical trials: NATALEE (ribociclib) and monarchE (abemaciclib).
7:25Â - Management of common side effects: diarrhea, neutropenia, hepatotoxicity.
10:51Â - Dosing strategies and dose modifications for toxicity.
12:28Â - Patient adherence challenges and strategies for education and support.
28:48Â - Handling comorbidities and drug-drug interactions in therapy selection.